



Biosfer Teslab

Advancing testing

Welcome to a new edition of the Biosfer Teslab newsletter.

During the second quarter of 2026, we continued to advance our research and innovation activities, consolidating ongoing projects and achieving new milestones across several strategic areas.

This period has been marked by the progress of our R&D&I initiatives, the achievement of new scientific and technological advances, and our active participation in events and collaborative initiatives that strengthen the health innovation ecosystem.

In this edition, we are pleased to share some of the most significant highlights from the past few months, reflecting our commitment to generating knowledge, fostering technology transfer, and developing innovative solutions with a meaningful impact on research and society.



PHONE: 34 977 07 10 30
EMAIL: INFO@BIOSFERTESLAB.COM
AVINGUDA DE CASTELLVELL, 18, BAIXOS,
43206 REUS, TARRAGONA



T2 2026



Scientific Publications

During the second quarter of 2026, Biosfer Teslab contributed to the publication of seven peer-reviewed scientific articles, highlighting our continued commitment to scientific excellence and innovation.

These publications reflect the strength of our collaborative research, the advancement of NMR-based metabolomics and precision medicine, and our dedication to generating high-quality scientific evidence with the potential to improve healthcare and patient outcomes.

1: Nordestgaard LT, Magni P, Sopić M, Chemaly M, Matic L, Dalila N, Trindade F, Wolford BN, Rodriguez-Hernandez Z, Amigó N, Catapano AL, Masana L, Devaux Y. Multiomics for Risk Stratification in Atherosclerotic Cardiovascular Disease. *Circ Genom Precis Med*. 2026 Apr;19(2):e005451. doi: 10.1161/CIRCGEN.125.005451. Epub 2026 Mar 25. PMID: 41878824; PMCID: PMC13102354.

2: Suárez-Díaz S, Miranda-Prieto D, López P, Alunno A, Pérez-Álvarez ÁI, Amigó N, Martínez-Zapico A, Suárez A, Rodríguez-Carrio J. Humoral responses against high-density lipoprotein are linked to unfavourable lipid and proteomic signatures in primary Sjögren's disease-a multi-platform approach. *Rheumatology (Oxford)*. 2026 May 5;65(5):keag141. doi: 10.1093/rheumatology/keag141. PMID: 41910589.

3: Bermúdez-López M, Nogales P, Martí-Antonio M, Castro-Boqué E, de Lamo VM, Beà-Menchón L, Luis-Lima S, Porrini E, Sanchez-Salguero X, Jové M, Obis E, Mota-Martorell N, Pérez-Gómez A, Garcia-Carrasco A, Bozic M, Guajardo J, Pérez-Sánchez CJ, Cambray S, Amigó N, Pamplona R, Bentzon JF, Valdivielso JM. Chronic kidney disease induces a distinct lipidomic signature and accelerates atherosclerosis progression in a novel minipig model. *Lab Anim Res*. 2026 Apr 2;42(1):10. doi: 10.1186/s42826-026-00274-w. PMID: 41928358; PMCID: PMC13045143.



British Society for
Rheumatology



Laboratory Animal
Research

T2 2026



Scientific Publications

4: Blanco-Echevarría A, Costa Segovia R, Guijarro Herraiz C, García Izquierdo B, Guadalix S, Pérez Carreras M, Rodríguez Gil Y, de Castro Martínez M, Amigó N, D'Avola D, Lumbreras Bermejo C, Martínez-Urbistondo D. Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics. PLoS One. 2026 May 13;21(5):e0343134. doi: 10.1371/journal.pone.0343134. PMID: 42127133; PMCID: PMC13170956.

5: Ibarretxe D, Tameish S, González-Lleó A, Cunillera E, Andreychuk N, Ballestin J, Cabello A, Cabau L, Amigó N, Grifoll C. Lipid profile and angiogenic markers in the detection of preeclampsia: The RECLAMA study. Clínica e Investigación en Arteriosclerosis. 2026 Jun. 500946. ISSN 0214-9168. doi: <https://doi.org/10.1016/j.arteri.2026.500946>.


6: Siurana JM, Martínez-Micaelo N, Samino S, Marimon C, Collell R, Girbau C, Sol Ventura P, Ortigosa E, Bosch Z, Sanz N, Sabaté-Rotés A, Yeste D, Fernández S, Sanchez-Gistau V, Bonada A, Plana N, Feliu A, Amigó N. Cardiovascular risk and metabolomic profile in adolescents: A comparative study between anorexia nervosa, normal weight, and obesity. Clin Investig Arterioscler. 2026 Jun 29:500955. English, Spanish. doi: 10.1016/j.arteri.2026.500955. Epub ahead of print. PMID: 42373366.

7: Amigó N , Dalli-Peydró E, Luis Díaz-Díaz J , Oterino A , Cabau L , Ballestín-Ballestín J ,Garcia-Moll X , Masana Ll . On behalf of IPE-NMR study group Show less. IMPACT OF ICOSAPENT ETHYL ON SERUM LIPO AND GLYCOPROTEIN PROFILES ASSESSED BY 1H-NMR. A REAL-WORLD OBSERVATIONAL STUDY (IPE-NMR) Nutrition, Metabolism and Cardiovascular Diseases. 2026, 104852. ISSN 0939-4753. DOI: <https://doi.org/10.1016/j.numecd.2026.104852>.





Advancing Our Projects



During the second quarter of 2026, Biosfer Teslab continued to make steady progress across its portfolio of research and innovation projects. Activities focused on advancing ongoing work packages, coordinating with national and international partners, analysing research data, and preparing upcoming project milestones.

In parallel, this quarter has also been dedicated to identifying new funding opportunities. Biosfer Teslab has actively participated in the preparation of several competitive proposals, joining collaborative consortia as both a project partner and, in selected initiatives, as the coordinating organisation. These efforts reinforce our long-term commitment to investing in research, fostering innovation, and translating scientific knowledge into solutions with real-world impact.



Students & Early Talent



The integration of students into Biosfer Teslab reflects our commitment to education and the development of emerging talent. Their involvement in real research projects brings fresh perspectives and new ideas that enrich our team, while also providing them with valuable hands-on experience in an innovative and multidisciplinary environment.

I'm **Antoni Llop**, a Computer Engineering student currently doing my internship at Biosfer Teslab. I'm passionate about technology and software development, and this internship gives me the opportunity to apply my knowledge in a real-world scientific and healthcare environment.

My name is **Eudald Rodríguez**. I hold a Bachelor's degree in Biochemistry and I am currently studying the Interuniversity Master's Degree in Metabolism and Nutrition at the University of Barcelona (UB) and the Universitat Rovira i Virgili (URV). I have joined Biosfer Teslab to expand my knowledge in biostatistics while developing my Master's Thesis in a research-oriented environment.

I'm **Núria Martin**, a Biotechnology student doing my university internship in Biosfer Teslab during summer 2026. I have a great interest in applying and developing my knowledge in this company. I'm passionate about laboratory research and computational research and I have the opportunity to combine both fields in this internship.

Cardioscope Project



The European project CardioSCOPE, funded by the Marie Skłodowska-Curie Actions under Horizon Europe, promotes collaboration between different organisations involved in cardiovascular research. The consortium brings together universities, hospitals and companies from several European countries. One of the main activities of the project is the exchange of researchers through temporary stays at partner institutions, where they can learn new techniques, share knowledge and work with experts from different fields. These experiences encourage international cooperation and contribute to the training and professional development of researchers. They also help generate new ideas and support the development of innovative ways to prevent, detect and predict cardiovascular diseases, ultimately contributing to better public health.

RESEARCHERS WHO HAVE VISITED OR COMPLETED THEIR SECONDMENTS



Cardioscope Project



INCOMING SECONDED RESEARCHERS

My name is **Zixiong Tang**, I graduated in Pharmaceutical Chemistry and Technology at University of Milan with a thesis in the field of pharmacognosy, focusing in particular on the anti-inflammatory effect of Sumac extract at the cutaneous level. Currently I am second-year PhD student at University of Milan, and my research focuses on the characterization of lipid membranes and the cargo content of extracellular vesicles, as well as their role in cardiometabolic disease. My work mainly focuses on cellular models and I have experience with standard laboratory techniques routinely used in molecular and cellular biology.

ZIXIONG TANG



IVA PEROVIC

During her secondment at Universitat Rovira i Virgili (URV) as part of the MSCA SE CardioSCOPE project, Dr. Iva Perović Blagojević visited Biosfer Teslab.

Her expertise and experience enriched our team through scientific discussions, knowledge exchange, and collaborative work, strengthening international cooperation and supporting our shared research goals.



CardioSCOPE
Empowering scientists for the "omics" era



Cardioscope Project



Experience

I am **Fabiola Castaldo**, a PhD student in Experimental Pharmacology at the University of Ferrara, Italy. My research focuses on cardiometabolic diseases, particularly type 2 diabetes, postprandial metabolism, and cardiovascular risk biomarkers. I also work as a Clinical Research Coordinator, supporting the management of clinical studies. During my three-month PhD secondment at Biosfer Teslab in Reus, Spain, I worked with clinical databases from patients with familial hypercholesterolemia, analyzing metabolomic and lipoprotein profiles using NMR technology. I also gained hands-on experience in laboratory workflows and participated in clinical study visits, strengthening my understanding of translational research. This experience allowed me to develop practical skills in R for data analysis and reinforced my interest in integrating biology, medicine, and data science. It inspired me to pursue further training in bioinformatics and continue building a career in translational, data-driven biomedical research aimed at improving patient care.



T2 2026

Events and conferences



8-04-2026 :Núria Amigó, Sara Samino Gene, and Pablo Ortiz attended this seminar, which focused on the potential of NMR-based metabolomics and its applications in both research and clinical practice as a tool for patient diagnosis and stratification.




17-04-2026 :Núria Amigó attended the IRB Lleida Metabolomics Seminar, which focused on the latest advances and applications of metabolomics in biomedical research, highlighting its potential to improve patient diagnosis, stratification, and precision medicine.



29/30-04-2026 :During the Female Heart Workshop, Núria Amigó, from Universitat Rovira i Virgili (URV), delivered a talk on molecular markers during menopause and their potential to enable personalized assessment of cardiovascular disease risk in women.



12-05-2026 :Núria Amigó took part in a conference organized by the Open University of Catalonia on the future of bioengineering in healthcare, where she shared her perspective on precision medicine and the importance of integrating clinical and omics data with artificial intelligence to improve healthcare decision-making.



T2 2026

Events and conferences



13-05-2026 :Núria Amigó represented Biosfer Teslab at the first Speed Dating event organized by the Hub Foodtech & Nutrition, an initiative designed to foster collaboration between companies, research centers, and stakeholders in the agri-food sector. The event also highlighted the opportunities of applying artificial intelligence to drive innovation in the agri-food industry.



24/27-05-2026 :Núria Amigó attended the EAS Congress, where she explored the latest advances in cardiovascular research and connected with leading international experts, exchanging knowledge on emerging biomarkers and precision medicine.



4/5-06-2026 :Núria Amigó participated in the Archamps Summer School, where she shared knowledge with students, researchers, and healthcare professionals on the application of data science, artificial intelligence, and digital health to drive innovation in cardiovascular healthcare.





sea
Sociedad Española
de Arteriosclerosis

17-19 June 2026

XXXVIII CONGRESO SEA



The 38th National Congress of the Spanish Society of Arteriosclerosis (SEA), held in Las Palmas de Gran Canaria from June 17 to 19, 2026, brought together nearly 600 specialists to discuss the latest advances in cardiovascular disease prevention and treatment.



As part of the 38th National Congress of the Spanish Society of Arteriosclerosis (SEA), a roundtable session was held to discuss recent advances in the diagnosis and characterization of dyslipidemias, highlighting the role of emerging laboratory tools and their clinical applications.

The session was moderated by José Puzo (Hospital Universitario San Jorge, Huesca) and Lidia Ruiz (Hospital Universitario Dr. Negrín). **Josep Ribalta Vives** presented the role of ApoB in the 21st-century laboratory report, **Teresa Arrobas** Velilla discussed the detection of autoantibodies in the diagnosis of dyslipidemias and their complications, and **Nuria Amigó** addressed the current clinical implications of advanced molecular characterization by NMR.

THANK YOU FOR BEING PART OF OUR JOURNEY.
TOGETHER, WE CONTINUE TRANSFORMING SCIENCE
INTO IMPACT. WE LOOK FORWARD TO SHARING
MORE WITH YOU IN THE NEXT EDITION.



FOLLOW US